We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Transferred MicroRNAs Modulate Insulin Sensitivity in Models

By LabMedica International staff writers
Posted on 02 Oct 2017
Print article
Image: A scanning electron micrograph (SEM) showing the morphology of the bright and round shaped exosomes (Photo courtesy of the University of California, San Diego).
Image: A scanning electron micrograph (SEM) showing the morphology of the bright and round shaped exosomes (Photo courtesy of the University of California, San Diego).
Studies using mouse models revealed that certain microRNAs (miRNAs) capable of modulating glucose metabolism were transferred via exosomes from adipose tissue macrophages to insulin target cells where they induced insulin resistance or sensitivity.

MicroRNAs (miRNAs) are a family of noncoding 19- to 25-nucleotide RNAs that regulate gene expression by targeting messenger RNAs (mRNAs) in a sequence specific manner, inducing translational repression or mRNA degradation, depending on the degree of complementarity between miRNAs and their targets. Many miRNAs are conserved in sequence between distantly related organisms, suggesting that these molecules participate in essential processes. In fact, miRNAs have been shown to be involved in the regulation of gene expression during development, cell proliferation, apoptosis, glucose metabolism, stress resistance, and cancer.

Exosomes are cell-derived vesicles that are present in many and perhaps all biological fluids, including blood, urine, and cultured medium of cell cultures. The reported diameter of exosomes is between 30 and 100 nanometers, which is larger than low-density lipoproteins but much smaller than red blood cells. Exosomes, which contain RNA, proteins, lipids, and metabolites that are reflective of the cell type of origin, are either released from the cell when multivesicular bodies fuse with the plasma membrane, or they are released directly from the plasma membrane. Exosomes have specialized functions and play a key role in coagulation, intercellular signaling, and waste management.

Investigators at the University of California, San Diego (USA) worked with lines of genetically obese or lean mice. They reported in the September 21, 2017, online edition of the journal Cell that adipose tissue macrophages (ATMs) in obese mice secreted miRNA-containing exosomes (Exos), which caused glucose intolerance and insulin resistance when administered to lean mice. Conversely, ATM Exos obtained from lean mice improved glucose tolerance and insulin sensitivity when administered to obese recipients.

The investigators found that the microRNA miR-155 was one of the miRNAs overexpressed in obese ATM Exos, and earlier studies had shown that the well-known metabolic protein peroxisome proliferator-activated receptor gamma (PPAR gamma) was a miR-155 target. Furthermore, mice that had been genetically engineered to lack miR-155 were insulin sensitive and glucose tolerant compared to controls.

"The actions induced by exosomes as they move between tissues are likely to be an underlying cause of intercellular communication causing metabolic derangements of diabetes," said senior author Dr. Jerrold Olefsky, professor of medicine at the University of California, San Diego. "By fluorescently labeling cells, we could see exosomes and the microRNA they carry moving from adipose (fat) tissue through the blood and infiltrating muscle and liver tissues."

"This is a key mechanism of how diabetes works," said Dr. Olefsky. "This is important because it pins the pathophysiology of the disease in inflamed adipose tissue macrophages which are making these exosomes. If we can find out which of the microRNAs in those exosomes cause the phenotype of diabetes, we can find drug targets."

Related Links:
University of California, San Diego

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
New
Ultra-Low Temperature Freezer
iUF118-GX

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Karius Focus BAL is designed to quickly identify the etiology of lung infections and improve diagnostic yield over standard of care testing (Photo courtesy of Karius)

Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections

Bronchoalveolar lavage (BAL) is a commonly used procedure for diagnosing lung infections, especially in immunocompromised patients. However, standard tests often fail to pinpoint the exact pathogen, leading... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more